** Hong Kong shares of CanSino Biologics Inc 6185.HK climb 2.8% to HK$29, the highest since Jan. 7; on course for third straight session of gains
** Clinical-stage vaccine company estimates its 2024 net loss narrowing to 335-385 mln yuan ($45.80-$52.63 mln) range from 1.48 bln yuan loss in 2023, with revenue amounting to 825-865 mln yuan range, as compared to 2023's 357.1 mln yuan revenue
** "During the reporting period, the group mainly focused on advancing commercialization of the meningococcal conjugate vaccines and the development of non-COVID-19 vaccine candidates" - CanSino
** Shanghai-listed stock 688185.SS rises 2.4% to 58.78 yuan, highest since Jan. 7; set for the second session of rise
** In China, the blue-chip CSI 300 Index .CSI300 gains 0.9% and the Shanghai Composite Index .SSEC adds 0.5%
** In Hong Kong, the healthcare index .HSCIH jumped 2.5% and Hang Seng Index .HSI rises 2.3%
** Last year, CanSino's Hong Kong stock rose 33.8%, while Shanghai shares fell 18.1%
($1 = 7.3148 yuan)
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.